REMICADE Antitrust Settlement Receives Final Approval
LexBlog IP
APRIL 12, 2023
The class action plaintiffs alleged that J&J “worked to suppress competition and raise prices to purchases of [REMICADE] by imposing a web of exclusionary contracts on both health insurers and healthcare providers.” The court preliminarily approved the settlement in August 2022. million in expenses.
Let's personalize your content